Trending

ema

EMA freezes UK representatives out of drug reviews as Brexit looms

EMA freezes UK representatives out of drug reviews as Brexit looms

The UK’s drugs regulator is increasingly being frozen out of work with the European Medicines Agency (EMA) according

X

EMA freezes UK representatives out of drug reviews as Brexit looms

https://pharmaphorum.com/news/ema-freezes-uk-representatives-out-of-drug-reviews-as-brexit-looms/

Neurofibromatosis treatment granted orphan status by EMA

AstraZeneca and Merck & Co. announced the European Medicines Agency (EMA) has granted orphan designation to their codeveloped

X

Neurofibromatosis treatment granted orphan status by EMA

https://pharmaphorum.com/news/nf1-treatment-granted-orphan-status-ema/

EMA warns Brexit move will cause higher-than-expected staff losses

EMA warns Brexit move will cause higher-than-expected staff losses

Europe’s medicines regulator is expecting higher-than-anticipated staff departures as a result of its Brexit-induced move from London to

X

EMA warns Brexit move will cause higher-than-expected staff losses

https://pharmaphorum.com/news/ema-brexit-staff-losses-amsterdam/

UK pharma calls for cooperation as EMA continues Brexit split

UK pharma calls for cooperation as EMA continues Brexit split

Britain’s pharma trade body has issued a fresh Brexit warning, saying it would be disadvantageous to both the

X

UK pharma calls for cooperation as EMA continues Brexit split

https://pharmaphorum.com/news/uk-pharma-calls-for-cooperation-as-ema-continues-brexit-split/

Dangerous inflammation prompts worldwide withdrawal of MS drug

Dangerous inflammation prompts worldwide withdrawal of MS drug

Biogen and AbbVie have announced the voluntary withdrawal of their multiple sclerosis drug Zinbryta from all markets worldwide

X

Dangerous inflammation prompts worldwide withdrawal of MS drug

https://pharmaphorum.com/news/dangerous-inflammation-prompts-worldwide-withdrawal-ms-drug/

EU cancer drugs rejection shows contrasts with FDA

EU cancer drugs rejection shows contrasts with FDA

Europe’s expert medicines panel has rejected Puma Biotechnology’s breast cancer drug neratinib, citing limitations in its efficacy and safety

X

EU cancer drugs rejection shows contrasts with FDA

https://pharmaphorum.com/news/eu-rejection-cancer-drugs-shows-differences-fda/

Pharma looking for progress as Brexit talks restart

Pharma looking for progress as Brexit talks restart

Pharma hoping for mutual recognition arrangement

X

Pharma looking for progress as Brexit talks restart

https://pharmaphorum.com/news/pharma-looking-progress-brexit-talks-restart/

Concerns over UK’s fading influence after EMA departure

Concerns over UK’s fading influence after EMA departure

This week’s decision to relocate the European Medicines Agency to Amsterdam has been greeted as the least damaging

X

Concerns over UK’s fading influence after EMA departure

https://pharmaphorum.com/transversal-categories/healthcare/concerns-european-medicines-agency-relocation/

EMA’s post-Brexit location to be decided today

EMA’s post-Brexit location to be decided today

The location of the European Medicines Agency after Brexit is to be decided today, as representatives of member

X

EMA’s post-Brexit location to be decided today

https://pharmaphorum.com/news/european-medicines-agency-relocation/

«< 3 4 5 6 7 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com